According to two pharmaceutical company sources, drug makers have been warned that the Trump administration is considering linking US drug prices to lower amounts paid by other developed countries, which is the top concern of the pharmaceutical industry. Sources said they expect the policy to come from the agency that oversees Medicare and Medicaid programs. The first source said that government health officials directly told him they were studying such policies, which he said was a mid-level priority for the Trump administration to try to lower drug prices. The two sources said that compared to other government initiatives currently being discussed (including imposing tariffs on imported drugs), such policies have a greater impact on the pharmaceutical industry. This is “the biggest existential threat to the industry and US bioscience innovation,” the first source said. (Reuters)